
Oligomerix
US-based Oligomerix develops novel therapeutics for Alzheimer's and related dementias by targeting tau self-association.
- 12
- Series B
Founded in Valhalla, United States, Oligomerix is a biotechnology company dedicated to developing disease-modifying therapeutics for Alzheimer’s disease and related dementias. The company's core mission is to target tau self-association to halt the progression of these neurodegenerative diseases. Oligomerix's drug discovery platform has identified a pipeline of novel small molecule inhibitors, including their lead candidate OLX07010, aimed at treating both common and rare tauopathies.
Oligomerix has garnered attention through its innovative approach and has published significant preclinical data supporting its therapeutic strategies. The company collaborates with various scientific advisory boards and partners to advance its research. Notable achievements include securing patents for their technology and progressing their lead candidate through preclinical stages. Oligomerix's impact lies in its potential to revolutionize the treatment landscape for Alzheimer's and other tau-related diseases.
Similar Companies

Allyx Therapeutics
allyxthera.com

Adrx
adrxpharma.com

AltPep
altpep.com

Ilios
iliostx.com

T3D Therapeutics

Alzheon
alzheon.com

Initial Therapeutics
initialtx.com

Novopyxis
novopyxis.com

Atelerix Life Sciences

Olatec Therapeutics
olatec.com

OrphoMed
orphomed.com
Sonexa Therapeutics

Omeros
omeros.com

Ceramedix Holding
ceramedix.com

Oscillo Biosciences
Quick Facts
Who are Oligomerix's competitors?
Companies similar to Oligomerix include Allyx Therapeutics, Adrx, AltPep and Ilios.
When was Oligomerix founded?
Oligomerix was founded in 2006.
Where is Oligomerix's headquarters located?
Oligomerix's headquarters is located in New York City, NY, US.
When was Oligomerix's last funding round?
Oligomerix's most recent funding round was for $3.4M (USD) in August 2022.
How much disclosed funding has Oligomerix raised?
As of Aug 9, 2022, Oligomerix has disclosed funding of $17.6M (USD). Undisclosed round amounts are excluded.
How many employees does Oligomerix have?
Oligomerix has 12 employees as of Feb 5, 2024.
Classification
- Ownership
- Technology
- Geographic Exposure
- Customer
- Main Product
- NAICS
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- SIC
- 8700Engineering, Accounting, Research, Management, And Related Services
- 8730Research, Development, And Testing Services
- 8731Commercial Physical and Biological Research
Show 13 more industry codes
- NAICS
- 320000Manufacturing
- 325400Pharmaceutical and Medicine Manufacturing
- 620000Health Care and Social Assistance
- 325000Chemical Manufacturing
- 623000Nursing and Residential Care Facilities
- 325410Pharmaceutical and Medicine Manufacturing
- 325412Pharmaceutical Preparation Manufacturing
- SIC
- 2800Chemicals And Allied Products
- 8000Health Services
- 2830Drugs
- 8040Offices And Clinics Of Other Health Practitioners
- 2834Pharmaceutical Preparations
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified